The clock is ticking, but not everyone hears it. While the European Parliament’s extension of the EU MDR (2017/745) transition period to 2027 and 2028 provided a much-needed lifeline for the MedTech industry, it also created a dangerous sense of complacency. For manufacturers of Legacy Devices, this isn’t a “wait and see” period – it is a high-stakes sprint to overhaul technical documentation before the window slams shut. At the center of this regulatory storm is the Clinical Evaluation Report (CER).
If your current CER still looks like it did under the old MDD, you are effectively holding an expired ticket. Notified Bodies are no longer accepting “equivalence” at face value or relying on thin literature reviews; they are demanding robust, proactive clinical evidence. As the 2027/2028 deadlines approach, the question isn’t just whether your device is safe, but whether your CER can prove it under the most rigorous scrutiny in the history of European healthcare.
The 2027/2028 Timeline: Understanding the Urgency
The extensions granted under Regulation (EU) 2023/607 depend on the risk class of the device:
- December 31, 2027: Deadline for Class III and Class IIb implantable non-well-established technologies.
- December 31, 2028: Deadline for other Class IIb, Class IIa, and Class I devices requiring Notified Body involvement.
To benefit from these extensions, manufacturers must have already submitted a formal application for MDR transition and established a compliant Quality Management System (QMS). However, the most common reason for “clock-stops” during the review process is insufficient clinical evidence within the CER. Waiting until 2026 to finalize your CER for a 2027 deadline is a high-risk strategy that could lead to your product being pulled from the EU market.
The Countdown Strategy: Strengthening Your CER Before Time Runs Out
With the deadlines looming, “business as usual” is a recipe for a market exit. To survive the final countdown, your update strategy must shift from passive reporting to active evidence generation.
Step 1: The “Red Flag” Gap Analysis
Don’t just read your old CER – audit it against the latest MDCG 2020-6 guidance for legacy devices. Identify where your “Equivalence” claims are weakest. Under MDR, the “equivalence pathway” has narrowed significantly. For Class III and implantable devices, you must have a contract in place allowing full access to the technical documentation of the equivalent device – a hurdle that is often impossible for competitors. If you are relying on a competitor’s data without this, you have a critical gap that must be addressed immediately.
Step 2: Modernizing State of the Art (SOTA)
In the eyes of a Notified Body, “Legacy” does not mean “grandfathered.” Your device must be compared against the current clinical standards, not the standards from when it was first launched. If clinical practices have evolved since your last update, your legacy device’s benefit-risk profile must be re-evaluated against these new benchmarks. Your CER must explain – with data – how your device still provides a favorable benefit-risk ratio in this modern landscape.
Step 3: Weaponizing PMCF Data
The transition period was granted specifically so manufacturers could gather the data they lacked. Your Post-Market Clinical Follow-up (PMCF) is your strongest weapon.
- Proactive Data Collection: Deploy high-quality clinical surveys or registry mining to gather real-world performance data.
- Bridge the Gaps: Use PMCF to fill specific data gaps identified during your gap analysis, such as data for specific sub-populations or long-term safety.
- Consistency Check: Ensure your PMCF findings flow seamlessly into your PSUR (Periodic Safety Update Report) and ultimately update the CER findings.
Step 4: The Resource Lockdown
As the 2027/2028 deadlines approach, the industry will face a “bottleneck” of clinical writers and Notified Body availability. Securing your technical expertise and submitting your application well ahead of the legal cutoff is the only way to avoid the “final hour” rush that is currently stalling hundreds of certifications
Common Pitfalls to Avoid
- Vague Benefit-Risk Analysis: You must quantify benefits and risks wherever possible. Vague statements like “the device is safe because we haven’t had many complaints” are no longer acceptable.
- Ignoring the “Intended Purpose”: Ensure your clinical data covers every specific claim and intended use listed on your Instructions for Use (IFU).
- Outdated Literature Searches: Literature searches must be systematic, reproducible, and recent (usually within the last 5 years).
- Lack of Expert Sign-off: The CER must be authored and reviewed by individuals with relevant clinical and technical qualifications as per MDR requirements.
Conclusion: The Cost of Hesitation
The extension is a bridge, not a destination. For Class III and IIb implantable devices, the December 2027 deadline is closer than it appears when you factor in the 12–18 month review cycles typical of Notified Bodies today. By the time 2028 arrives for Class IIa and I devices, the scrutiny will only have intensified.
Is your documentation strong enough to survive the final review? Don’t let your legacy device become a casualty of the transition. Ensure your Clinical Evaluation Reports are MDR-compliant, data-driven, and ready for submission with professional support. MakroCare specializes in identifying clinical gaps, conducting systematic literature reviews, and authoring high-impact CERs that meet the most stringent regulatory demands.
Secure your 2027/2028 transition with Clinical Evaluation Report (CER) services by MakroCare.
